Reading Time: < 1 minute
Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.
Read the article at biostock.se:
Elicera’s candidate ELC-100 granted Orphan Drug Designation
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
